Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$16.73 -4.9%	$19.22	$10.21 ▼ $25.67	$4.20B	0.43	3.66 million shs	3.84 million shs
AUTL Autolus Therapeutics	$2.41 -0.4%	$2.04	$1.11 ▼ $5.00	$644.06M	1.81	1.57 million shs	1.50 million shs
GRTS Gritstone bio		$0.35	$0.03 ▼ $3.17	$3.50M	0.49	7.01 million shs	61.02 million shs
HARP Harpoon Therapeutics	$23.01	$22.89	$3.11 ▼ $23.21	$389.61M	2.11	1.52 million shs	N/A
STRO Sutro Biopharma	$0.76 -0.8%	$0.82	$0.52 ▼ $5.17	$64.69M	1.64	1.11 million shs	205,689 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-0.57%	-4.76%	-6.88%	-17.46%	+32.36%
AUTL Autolus Therapeutics	-0.82%	-2.42%	+19.21%	+69.23%	-45.37%
GRTS Gritstone bio	0.00%	0.00%	0.00%	0.00%	-95.40%
HARP Harpoon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
STRO Sutro Biopharma	+1.20%	-6.35%	-3.06%	+45.06%	-81.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8794 of 5 stars	3.7	1.0	0.0	0.0	2.9	2.5	3.1
AUTL Autolus Therapeutics	2.6855 of 5 stars	3.5	1.0	0.0	0.0	2.6	3.3	0.6
GRTS Gritstone bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HARP Harpoon Therapeutics	0.7603 of 5 stars	0.0	0.0	0.0	4.7	0.6	2.5	0.0
STRO Sutro Biopharma	4.2057 of 5 stars	3.1	5.0	0.0	4.7	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	65.37% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	286.72% Upside
GRTS Gritstone bio	2.50	Moderate Buy	$2.17	∞ Upside
HARP Harpoon Therapeutics	0.00	N/A	N/A	N/A
STRO Sutro Biopharma	2.25	Hold	$6.11	704.51% Upside

Current Analyst Ratings Breakdown

Latest ADMA, AUTL, GRTS, STRO, and HARP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$2.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.37	$0.51 per share	32.50	$1.48 per share	11.30
AUTL Autolus Therapeutics	$10.12M	63.38	N/A	N/A	$1.61 per share	1.50
GRTS Gritstone bio	$496K	0.00	N/A	N/A	$0.54 per share	0.00
HARP Harpoon Therapeutics	$37.34M	10.43	N/A	N/A	$1.63 per share	14.12
STRO Sutro Biopharma	$62.04M	1.03	N/A	N/A	$0.54 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	31.41	24.25	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
AUTL Autolus Therapeutics	-$220.66M	-$0.88	0.00	N/A	N/A	N/A	-52.82%	-29.67%	8/14/2025 (Estimated)
GRTS Gritstone bio	-$138.49M	-$1.24	N/A	N/A	N/A	-910.50%	-328.51%	-82.53%	N/A
HARP Harpoon Therapeutics	-$67.73M	-$8.76	N/A	N/A	N/A	-81.68%	-893.55%	-45.98%	N/A
STRO Sutro Biopharma	-$227.46M	-$2.98	0.00	N/A	N/A	-373.66%	-347.60%	-59.46%	8/12/2025 (Estimated)

Latest ADMA, AUTL, GRTS, STRO, and HARP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/12/2025	Q2 2025	STRO Sutro Biopharma	-$0.53	N/A	N/A	N/A	$14.55 million	N/A
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
GRTS Gritstone bio	N/A	N/A	N/A	N/A	N/A
HARP Harpoon Therapeutics	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
AUTL Autolus Therapeutics	N/A	9.24	9.02
GRTS Gritstone bio	1.83	2.54	2.54
HARP Harpoon Therapeutics	N/A	1.89	1.89
STRO Sutro Biopharma	N/A	2.16	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AUTL Autolus Therapeutics	72.83%
GRTS Gritstone bio	48.46%
HARP Harpoon Therapeutics	74.01%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AUTL Autolus Therapeutics	25.70%
GRTS Gritstone bio	4.61%
HARP Harpoon Therapeutics	17.00%
STRO Sutro Biopharma	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
GRTS Gritstone bio	190	108.57 million	111.84 million	Optionable
HARP Harpoon Therapeutics	53	16.93 million	14.05 million	Optionable
STRO Sutro Biopharma	240	84.46 million	81.42 million	Optionable

ADMA, AUTL, GRTS, STRO, and HARP Headlines

Recent News About These Companies

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of "Hold" from Brokerages

July 11, 2025 | americanbankingnews.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from Brokerages

July 11, 2025 | marketbeat.com

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

June 16, 2025 | msn.com

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

June 2, 2025 | finance.yahoo.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025 | globenewswire.com

Sutro Biopharma to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%

April 26, 2025 | aaii.comA

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%

April 1, 2025 | aaii.comA

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%

March 18, 2025 | aaii.comA

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright

March 17, 2025 | markets.businessinsider.com

HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)

March 17, 2025 | msn.com

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

March 16, 2025 | markets.businessinsider.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%

March 15, 2025 | aaii.comA

Wedbush Downgrades Sutro Biopharma (STRO)

March 15, 2025 | msn.com

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

March 14, 2025 | markets.businessinsider.com

Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review

March 14, 2025 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside

ADMA, AUTL, GRTS, STRO, and HARP Company Descriptions

ADMA Biologics NASDAQ:ADMA

$16.73 -0.86 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$17.12 +0.39 (+2.33%)

As of 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Autolus Therapeutics NASDAQ:AUTL

$2.41 -0.01 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 -0.01 (-0.21%)

As of 06:41 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Gritstone bio NASDAQ:GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Sutro Biopharma NASDAQ:STRO

$0.76 -0.01 (-0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.77 +0.01 (+1.18%)

As of 07:55 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time